Meteda Buys Portuguese AI Ophthalmology Expert Retmarker

Meteda, an Italian designer and creator of software and hardware for chronic diseases and nutrition, has acquired Portuguese AI expert Retmarker. Retmarker focuses on the ophthalmology field, including diabetic retinopathy.
 
“Retmarker is one of the most respected providers of Artificial Intelligence technology for ophthalmology worldwide,” Marco Vespasiani, Meteda GM told the press. “Their state-of-the-art solutions for diabetic retinopathy allow very efficient and effective population-based screening programs to prevent the dramatic consequences linked to this common complication of diabetes.”
 
Diabetic retinopathy is a diabetes complication caused by high blood sugar levels damaging the retina. Over 400 million diabetes patients risk blindness due to the condition, and according to international guidelines should undergo periodic screening to identify the need for treatment.
 
“Retmarker automated artificial intelligence technology makes such process to become objective, scalable and affordable,” João Diogo Ramos, Retmarker Chairman and CEO, stated. “Meteda operates throughout the EMEA Region and is a leader for electronic medical record systems for diabetes clinics, serving more than 90 percent of diabetes centers in Italy, and one of the main players in the nutritional software area. Since our foundation, we have been focusing on innovative and unique solutions to improve people lifestyle and healthcare. The acquisition of Retmarker and their technologies is a further step forward.”
 
“Our deal with Meteda confirms the potential that we believe exists towards the usage of AI to cope with the several complications of diabetes. At Retmarker we all are very proud of what we achieved over the years. Now we are entering a new and stronger context to tackle the challenges and opportunities ahead”, Ramos said.
 
“Thanks to its experience in data management for diabetes care, Meteda started a new path into AI with the aim to make annual screening of retina feasible. We consider this acquisition as our first step into AI which can unfold many other opportunities for diabetes care in the next future”, Vespasiani concluded.